The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial

Archive ouverte

Cleland, John | Ferreira, João Pedro | Mariottoni, Beatrice | Pellicori, Pierpaolo | Cuthbert, Joe | Verdonschot, Job | Petutschnigg, Johannes | Ahmed, Fozia | Cosmi, Franco | Brunner La Rocca, Hans-Peter | Mamas, Mamas | Clark, Andrew | Edelmann, Frank | Pieske, Burkert | Khan, Javed | Mcdonald, Ken | Rouet, Philippe | Staessen, Jan | Mujaj, Blerim | González, Arantxa | Diez, Javier | Hazebroek, Mark | Heymans, Stephane | Latini, Roberto | Grojean, Stéphanie | Pizard, Anne | Girerd, Nicolas | Rossignol, Patrick | Collier, Tim | Zannad, Faiez | Atar, Dan | Kober, Lars | Dickstein, Kenneth | Lange, Theis

Edité par CCSD ; Oxford University Press (OUP) -

International audience. Aims: To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure.Methods and results: Randomized, open-label, blinded-endpoint trial comparing spironolactone (50 mg/day) or control for up to 9 months in people with, or at high risk of, coronary disease and raised plasma B-type natriuretic peptides. The primary endpoint was the interaction between baseline serum galectin-3 and changes in serum procollagen type-III N-terminal pro-peptide (PIIINP) in participants assigned to spironolactone or control. Procollagen type-I C-terminal pro-peptide (PICP) and collagen type-1 C-terminal telopeptide (CITP), reflecting synthesis and degradation of type-I collagen, were also measured. In 527 participants (median age 73 years, 26% women), changes in PIIINP were similar for spironolactone and control [mean difference (mdiff): -0.15; 95% confidence interval (CI) -0.44 to 0.15 μg/L; P = 0.32] but those receiving spironolactone had greater reductions in PICP (mdiff: -8.1; 95% CI -11.9 to -4.3 μg/L; P < 0.0001) and PICP/CITP ratio (mdiff: -2.9; 95% CI -4.3 to -1.5; <0.0001). No interactions with serum galectin were observed. Systolic blood pressure (mdiff: -10; 95% CI -13 to -7 mmHg; P < 0.0001), left atrial volume (mdiff: -1; 95% CI -2 to 0 mL/m2; P = 0.010), and NT-proBNP (mdiff: -57; 95% CI -81 to -33 ng/L; P < 0.0001) were reduced in those assigned spironolactone.Conclusions: Galectin-3 did not identify greater reductions in serum concentrations of collagen biomarkers in response to spironolactone. However, spironolactone may influence type-I collagen metabolism. Whether spironolactone can delay or prevent progression to symptomatic heart failure should be investigated.

Suggestions

Du même auteur

The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial

Archive ouverte | Cleland, John | CCSD

International audience. Abstract Aims To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure. Methods and results Randomized, open-label...

Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF

Archive ouverte | Ferreira, João Pedro | CCSD

International audience. Objectives: This study sought to further understand the mechanisms underlying effect of spironolactone and assessed its impact on multiple plasma protein biomarkers and their respective under...

Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial

Archive ouverte | Ferreira, João Pedro | CCSD

International audience. Abstract Aims Uncontrolled blood pressure (BP) increases the risk of developing heart failure (HF). The effect of spironolactone on BP of patients at risk of developing HF is yet to be determ...

Chargement des enrichissements...